Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX101 + Bevacizumab in Recurrent Platinum-Resistant Ovarian Cancer
NCT01652079Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2012
- Primary completion
- Mar 2018
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CRLX101 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Massachusetts General Hospital. Started Apr 2012; status: completed.
02
Drugs
CRLX101
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01652079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652079.